Reckitt Benckiser Group (LON:RKT) Trading 1.9% Higher – Still a Buy?

Reckitt Benckiser Group plc (LON:RKT) rose 1.9% during trading on Monday . The stock traded as high as GBX 5,172 ($64.39) and last traded at GBX 5,166 ($64.32). Approximately 90,327,430 shares were traded during mid-day trading, an increase of 757% from the average daily volume of 10,544,096 shares. The stock had previously closed at GBX 5,072 ($63.15).

Wall Street Analysts Forecast Growth

Separately, Berenberg Bank lowered their price objective on shares of Reckitt Benckiser Group from GBX 5,200 ($64.74) to GBX 5,177 ($64.45) and set a “hold” rating on the stock in a research report on Wednesday, October 23rd.

Reckitt Benckiser Group Stock Performance

The stock has a market capitalization of £36.24 billion, a P/E ratio of 2,416.59, a P/E/G ratio of 1.10 and a beta of 0.09. The business’s fifty day moving average price is GBX 4,883.66 and its two-hundred day moving average price is GBX 4,651.11. The company has a debt-to-equity ratio of 112.52, a quick ratio of 0.46 and a current ratio of 0.69.

Insiders Place Their Bets

In other Reckitt Benckiser Group news, insider Shannon Eisenhardt sold 1,368 shares of the company’s stock in a transaction that occurred on Tuesday, December 10th. The shares were sold at an average price of GBX 4,723 ($58.80), for a total transaction of £64,610.64 ($80,441.53). 0.05% of the stock is owned by company insiders.

About Reckitt Benckiser Group

Reckitt Benckiser Group plc manufactures and sells health, hygiene, and nutrition products worldwide. It offers acne treatment creams, facial washes, and cleansing pads; germ protection products; condoms; heartburn and indigestion solutions; joints health products; chest congestion, cough, and sinus remedies; brain health products; migraine-headaches and rheumatic pain products; sore throat medications; and hair removal products under the Airborne, Clearasil, Dettol, Durex, Gaviscon, Move Free, Neuriva, Nurofen, Mucinex, Strepsils, and Veet brands.